Corza Medical has acquired Katena products and eye surgery supplies. Katena manufactures eye products that are widely used in cataract, glaucoma and corneal surgery, including precision surgery, composite devices and special organ transplants, according to the newspaper. The company, which has more than 200 employees in North America and Europe, has sold products in 110 countries with more than 5,000 customers.

Corza said the announcement and acquisition will expand its surgical product portfolio and add a larger number, product line and equipment to its surgical department. This is Corza's first acquisition since its inception in January 2021, and the company is seeking to bring in "close" leaders in health technology. Corza was born from a combination of Specialty Surgery at TachoSil, originally from Takeda.

Integer Holdings (NYSE: ITGR) has announced that it has completed the acquisition of Oscar, a deal that expands its capacity to what is already one of the world's largest manufacturers of medical contracts.

Integer said the acquisition would cost $ 220 million when it first announced its plans in October.

DePuy Synthes of Johnson & Johnson (NYSE: JNJ) - with its Synthes GmbH - has announced the acquisition of OrthoSpin.

Israel OrthoSpin is developing an advanced repair system that helps with orthopedic treatment. The platform is integrated with DePuy Synthes' Maxframe Multiaxial Correction System, an external ring processing system.

OrthoSpin received FDA approval for second-generation robotics in the digital External G2 system in January of this year.

According to the newspaper, the acquisition reflects J&J's efforts to promote innovation in medical technology, where the company has been focusing on OrthoSpin for many years. OrthoSpin raised $ 3 million for the External Repair System and investment program in July 2018 led by J&J. The company also launched OrthoSpin Series B in March 2020.

DePuy Synthes introduced their Maxframe system in 2017 and released a new framework with the next software planned. The industry experts believe that getting OrthoSpin makes DePuy a better place to serve health professionals and patients during the complexities of recovery after surgery.

Once acquired, DePuy Synthes plans to integrate OrthoSpin and create a supply chain before launching the product in multiple locations and in the "near future". The financial status of the acquisition has not been disclosed. 

BD (NYSE: BDX) recommends getting Venclose and its solution for the treatment of chronic venous insufficiency (CVI). CVI occurs as a result of valve obstruction and can lead to varicose veins. Venclose CVI treatment uses radiofrequency (RF) ablation technology, and its catheters can reduce pain and ulcers later compared to other laser treatments.

The Venclose system has a compact design with two light bulbs (2.5cm and 10cm) and a 6 FR catheter. The design, according to BD, allows doctors to remove other veins more effectively during any warm-up process thanks to its increased temperature compared to competitors RF ablation catheters.

Dual heating allows doctors to use a single catheter to remove long and short venous segments, reducing product overhead compared to catheters with short and / or static temperatures. The system also displays a touch screen and audible sound for light transmission to enhance the patient and physician experience.

Venclose systems are currently available at various health facilities in the United States and parts of Europe, BD said, based in Franklin Lakes, New Jersey.
The financial structure of the business has not been disclosed. BD expects that acquisition will not be necessary in the context of its 2022 budget results.